PrimeGen Biotech Creates VetCell Therapeutics Subsidiary – Prioritizes Deployment of Cell Therapies for Improving Quality of Life of Pets Living with Degenerative Diseases

 

VetCell to Offer Advanced Therapies Utilizing Allogeneic and Autologous Stem Cells Derived from Various Tissues for Treatment of Degenerative and Autoimmune Disorders in Pets

 

SANTA ANA, Calif., June 25, 2015 – PrimeGen Biotech, a pioneer in the research and discovery of practical therapeutic uses for stem cells, today announced the opening of its VetCell Therapeutics subsidiary. The VetCell team within PrimeGen is dedicated to the research and development of safe and affordable new therapies for pets and companion animals through the use of many types of stem cells. This announcement builds upon PrimeGen Biotech’s recent announcement of the opening of a new 10,000 square-foot research facility located in Santa Ana, CA, from which VetCell Therapeutics will operate. As a subsidiary of PrimeGen Biotech, VetCell Therapeutics has rights to use its parent company’s more-than 30 issued and pending patents regarding the use of stem cells for regenerative medical applications.

“We started PrimeGen more than a decade ago with a mission to make significant discoveries in the therapeutic properties of stem cells in combatting the effects of various diseases and to apply that knowledge gained to the development of top-quality treatments that could be afforded by anyone,” said Tom Yuen, CEO of PrimeGen Biotech, LLC. “With VetCell, our mission is exactly the same, and we plan to work with veterinarians around the world to ensure that their pet and companion animal owners have access to advanced stem cell therapies. We strongly feel that anybody should be able to afford the best quality treatment for their sick or aging pets and companion animals.”

VetCell Therapeutics’ current line of patented and patent pending regenerative medicines includes cell therapies for sick and aging animals based on stem cells derived from adipose tissue, capable of treating a wide range of ailments, including severe pain and inflammation resulting from various degenerative osteoarthritic conditions to organ failure and autoimmune diseases. VetCell is enlisting the collaboration of veterinarians worldwide to conduct clinical trials of the company’s patented techniques. The research scientists at VetCell are continuously investigating effective future medicines that utilize both allogeneic and autologous stem cells derived from sources other than adipose tissue, such as bone marrow, blood and various organ tissues, as well as exploring new processing techniques. VetCell’s services include banking of cells for later use, ability to culture or grow more cells for retreatment, eliminating the need for pets to withstand multiple adipose tissue biopsies.

“Through our research, we have learned that different cell products each offer different therapeutic value. Because of this understanding, we design specific products that utilize specialized cells that offer the best therapeutic properties for specific diseases,” added Dr. Fari Izadyar DVM, PhD, Chief Scientific Officer at PrimeGen Biotech LLC.

PrimeGen’s and VetCell’s ongoing research has shown promising signs that stem cells derived from various tissues in the body may serve specialized medical purposes; PrimeGen’s new facility and home of VetCell Therapeutics was designed to give its team of scientists the space and tools necessary to delve deeper into the characterization of stem cells and their respective therapeutic value, and to develop potent treatments, while complying with FDA’s Current Good Manufacturing Practice (CGMP) regulations, ensuring a safe and high quality product for clinical use.

 

To learn more about VetCell Therapeutics and the company’s product offering, please visit www.vetcelltherapeutics.com. To learn more about PrimeGen Biotech and its research, please visit www.primegenbiotech.com.

 

# # #

 

 

About VetCell Therapeutics:

Vet Cell Therapeutics (VCT) is a cell therapy company focused on generating regenerative treatments for companion animals.   The core technology of the treatment is with the use of your pet’s adipose stem cells.  Our goal is to use these cells for companion animals to treat osteoarthritis, lameness, and other degenerative diseases.

 

 

PrimeGen Biotech LLC:

Founded in 2002, PrimeGen Biotech is a privately-held research firm dedicated to discovering the best possible applications for stem cell therapies and translating its research into effective therapeutic applications. PrimeGen Biotech is located in Santa Ana, California and operates a 10,000 sq ft facility.  The newly renovated facility consists of modern laboratories capable of cell processing, cell culture, molecular biology, flow cytometry, and histology.  The laboratories are designed specifically to meet the requirements of our unique research approaches. The PrimeGen team includes research scientists and specialists with decades’ experience researching adult stem cells.